FOOD AND DRUG ADMINISTRATION
Center for Drug Evaluation and Research

Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) Meeting
FDA White Oak Campus, Building 31, The Great Room (Rm. 1503)
White Oak Conference Center, Silver Spring, Maryland
February 22, 2012

Questions to the Committee

1. Discuss your interpretation of the available data presented regarding teratogenicity of topiramate, including whether the data indicate an increase in the risk for oral clefs.

2. Discuss the potential strengths and weaknesses of the proposed teratogenicity risk management strategy for phentermine/topiramate (PHEN/TPM).

3. Taking into account the reported changes in antihypertensive therapy, discuss the clinical significance of the changes in blood pressure and heart rate in overweight and obese patients treated with PHEN/TPM versus placebo.

4. Discuss whether the available data for PHEN/TPM warrant that a cardiovascular outcomes trial be conducted prior to approval.

5. Considering all the available data included in the application and today's discussions, does the overall benefit-risk assessment of PHEN/TPM support its approval for the treatment of obesity in individuals with a body mass index (BMI) $\geq$ 30 kg/m^2 or $\geq$ 27 kg/m^2 with weight-related co-morbidities? (VOTING)

    a. If you voted "Yes" in question #5, please provide your rationale and comment on the approach to post-approval risk management.

    b. If you voted "No" in question #5, please provide your rationale and comment on what additional clinical data would be required to support approval.